IV Push Medications

This article has been archived.
Please use for reference only.

Penn Home Infusion Team
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001

Share article


Imprima English

You will need the following supplies:

  • ____ vials of ________________
  • ____ cc syringe with needle
  • ____ cc syringe
  • ____ 25 gauge 1" needle
  • ____ Normal Saline or Dextrose 5%/water (circle one) ____ cc minibag
  • ____ alcohol wipes
  • ____ antibacterial soap
  1. Prepare a clean work area.
  2. Wash your hands (see Handwashing section for more information).
  3. Flip off the plastic protective cap of the medication vial .
  4. Wipe the top of the vial, with an alcohol wipe. Allow to dry.
  5. Check medication vial to make sure it is the correct medication and strength. Also check to be certain it has not expired.
  6. Check minibag to make sure it is the correct fluid and volume.
  7. Wipe the injection cap of the administration port on the minibag with a new alcohol wipe. Allow to dry. Set aside on clean work area.
  8. Remove cap from syringe and attach needle to syringe.
  9. Pull the syringe plunger back to _____ cc.
  10. Remove needle cap and set it on clean work area for later use. Insert needle into US center of rubber stopper of medication vial.
  11. Invert the vial with the needle still inserted. Inject the air into the vial. Be sure that the tip of the needle is in solution and draw back to _____ cc. Be careful not to draw up air.
  12. Withdraw the needle from the vial.
  13. Insert the needle into the injection cap of the administration port on your minibag. Inject all the medication.
  14. Shake the minibag well to mix the medication.
  15. Use prepared minibag within _____ hours since potency may decrease after this period.
  16. Attach tubing to minibag.

Imprima English
News
Stage III/IV Melanoma Patients at Risk for New Primaries

Dec 10, 2013 - Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas, although the incidence rates are lower than those observed in studies of dabrafenib and vemurafenib, according to research published online Dec. 2 in the Journal of Clinical Oncology.



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información